LGD-4033

Selective Androgen Receptor Binding#

LGD-4033 is a non-steroidal small molecule that binds the androgen receptor (AR) with high affinity (Ki ≈ 1 nM) and — critically — binds it selectively in anabolic tissues. In skeletal muscle and bone, LGD behaves as a full AR agonist, driving transcription of the same anabolic target genes that testosterone drives: IGF-1, MyoD, myogenin, and downstream myofibrillar protein synthesis machinery. In prostate and sebaceous tissue, it recruits a different cofactor set and behaves as a weak partial agonist. This is the entire pharmacological premise of a SARM: muscle and bone growth without the prostatic hypertrophy, oily skin, and androgenic hair loss that come with exogenous testosterone or DHT.

"LGD-4033 is a nonsteroidal SARM that binds the androgen receptor with high affinity, displaying substantial anabolic and functional activity in skeletal muscle and bone, while minimally stimulating the prostate." — Efimenko IV et al., Andrologia, 2021

Practically, this is why users on 10 mg/day get meaningful lean-mass gains without the acne and aggression profile of a dbol or anadrol run. The androgenic load is genuinely low — the anabolic:androgenic ratio in animal models sits around 500:1 versus testosterone's ~1:1.

No Aromatization, No 5α-Reduction#

Unlike testosterone, LGD-4033 is not a substrate for aromatase or 5α-reductase. It does not convert to estradiol and it does not convert to DHT. This has two practical consequences the reader needs to understand before cycling:

1. No estrogenic water retention, no gyno risk from the compound itself. Gains look drier than a comparable test cycle.
2. Endogenous estradiol crashes along with testosterone. Because LGD suppresses your natural T (see below), and because LGD itself does not aromatize to replace that lost E2, users frequently end a cycle with symptomatically low estrogen — joint dryness, flat libido, poor mood, dead lifts feeling heavy.

This is the single most misunderstood part of the LGD experience. It is not a "dry gyno-free test" — it is a compound that occupies the AR while simultaneously starving you of the E2 your joints, libido, and CNS need.

HPTA Suppression via Hypothalamic AR Agonism#

LGD-4033 crosses the blood-brain barrier and activates AR in the hypothalamus. The hypothalamus reads this as "androgen levels are high" and shuts down GnRH → LH/FSH → endogenous testosterone production via standard negative feedback. Suppression is dose-dependent and shows up even at clinical microdoses.

"LGD-4033 administered for 21 days was safe, well tolerated, and had a favorable pharmacokinetic profile. LGD-4033 significantly increased lean body mass from baseline to day 22 even at the lowest 0.1-mg dose." — Basaria S et al., Journals of Gerontology Series A, 2013

In that same trial, 1 mg/day — one tenth of the standard community dose — already suppressed total testosterone, free testosterone, SHBG, and HDL. At 10 mg/day × 8 weeks, expect total T to drop 40–60%. This is why PCT is non-negotiable on a real LGD cycle, regardless of what older SARM-era marketing claimed.

Pharmacokinetics That Enable Once-Daily Dosing#

LGD-4033 is orally bioavailable (~90%), reaches Tmax within 1–4 hours, and has a plasma half-life of roughly 24–36 hours. Steady-state accumulation is reached within about five days of daily dosing.

"Oral administration of 10 mg LGD-4033 to a healthy volunteer revealed a long plasma half-life (approximately 24–36 hours), with phase I and phase II metabolites detected in urine up to 22 days post-administration." — Fragkaki AG et al., Drug Testing and Analysis, 2018

Two practical takeaways: dose timing doesn't matter — once-daily at whatever time you'll actually remember is fine — and tested athletes need to stay far away. Metabolites are detectable in urine for weeks after the last dose.

Hepatic Metabolism and the Lipid/LFT Picture#

LGD is not C17-alpha alkylated, so it does not carry the same direct hepatotoxic mechanism as oral AAS like anadrol or superdrol. It is, however, hepatically metabolized via CYP-mediated oxidation followed by glucuronidation, and isolated case reports of drug-induced liver injury exist.

"We describe the first reported case of drug-induced liver injury attributed to Ligandrol, confirmed by liver biopsy, which resolved upon discontinuation." — Barbara M et al., ACG Case Reports Journal, 2020

The lipid signature is more consistent than the LFT signature: AR agonism in hepatocytes reliably suppresses HDL and often raises LDL, an effect seen at all clinical doses and more pronounced at 10+ mg/day. This is the mechanistic reason the standard protocol includes mid-cycle and post-cycle bloodwork, cardio throughout, and a hard stop at 8 weeks — not vibes, but a predictable pharmacology you can plan around.

Common (most users)#

• HPTA suppression — expect total testosterone to drop 40–60% on a standard 10 mg × 8-week run, with LH/FSH and SHBG following. This is the expected effect, not a side effect. Mitigate with a proper mini-PCT (enclomiphene 12.5 mg/day × 4 weeks, or nolvadex 20/20/10/10) starting 24 h after the last dose, and cap cycle length at 8 weeks.

"LGD-4033 administered for 21 days was safe, well tolerated, and had a favorable pharmacokinetic profile... dose-dependent suppression of total testosterone, sex hormone–binding globulin, high-density lipoprotein cholesterol, and triglycerides was observed." — Basaria et al., 2013

• HDL drop / lipid shift — HDL falls, LDL often creeps up. Run daily cardio (zone 2, 20–30 min), 3–4 g/day EPA+DHA, keep saturated fat moderate, and pull bloods mid-cycle. Lipids normalize within weeks of cessation in most users.
• Mild water retention / fullness — muscles look fuller within 7–10 days; some users report a small scale jump from intracellular water. Not estrogenic — LGD doesn't aromatize. No mitigation needed.
• Low-E2 symptoms paradoxically — because endogenous T crashes, estradiol crashes with it. Dry joints, flat libido, mood blunting in weeks 4–8 are typical. An experienced fix is a low-dose testosterone base (TRT dose, 100–150 mg/week) or accepting the trough and letting PCT restore things.
• Lethargy — shows up mid-cycle in a minority, usually tracks suppression. Caffeine tolerance often rises. Not a reason to stop.

Uncommon (dose-dependent or individual)#

• Elevated blood pressure — more likely at 15–20 mg/day. Check BP weekly on cycle; if systolic creeps above 140, drop dose or add telmisartan/cialis per a physician. Don't run LGD on top of untreated hypertension.
• Mild LFT elevation (AST/ALT) — not a C17-aa compound, but transaminase bumps show up on mid-cycle bloods in some users, especially stacked with other orals or heavy alcohol. Pull LFTs at week 4. Trending up → stop.
• Testicular shrinkage / libido crash — standard signs of suppression. Cosmetic only; reverses with PCT. HCG 250–500 IU 2×/week on cycle prevents the visual change if it bothers you.
• Hair shedding in genetically predisposed users — LGD is not 5α-reduced, but AR agonism in the scalp is still AR agonism. Topical finasteride or RU58841 as part of a hair stack for anyone with MPB history.
• Virilization signs (women) — voice deepening, clitoral enlargement, acne, hair-pattern changes. Reported anecdotally above ~2 mg/day and potentially irreversible. Women wanting a SARM should use low-dose ostarine instead.

Rare but serious#

• Drug-induced liver injury (cholestatic) — documented case reports, usually resolving on discontinuation. Warning signs: jaundice, dark urine, pale stool, RUQ pain, pruritus. Stop immediately, get LFTs and a bilirubin panel.

"We describe the first reported case of drug-induced liver injury attributed to Ligandrol, confirmed by liver biopsy, which resolved upon discontinuation." — Barbara et al., 2020

• Severe lipid derangement — HDL below 20 mg/dL or LDL above 160 mg/dL on cycle warrants stopping. The Cardaci 2022 LGD+MK-677 case report documented meaningful HDL suppression alongside gains — the trade-off is real.
• Prolonged HPTA shutdown — rare, but recovery can stretch past 12 weeks in users who ran 20+ mg doses, long cycles, or stacked with suppressive compounds and skipped PCT. If bloods at week 6 post-PCT still show LH/FSH bottom-of-range and total T under 300, escalate to a proper SERM restart protocol.
• Cardiac symptoms — chest tightness, exertional dyspnea, resting tachycardia. Not common at reasonable doses, but the combination of low HDL + elevated BP + stimulant pre-workouts is a bad setup. Stop and investigate.

Hard contraindications#

• Pregnancy or active attempts to conceive — androgenic exposure is teratogenic; LGD suppresses spermatogenesis.
• Lactation.
• Concurrent C17-alpha-alkylated orals (anadrol, superdrol, dbol, winstrol) — stacking hepatotoxic pressure for zero anabolic synergy.
• Untreated hypertension or dyslipidemia — fix these first. LGD will make both worse.
• Active liver disease — any baseline hepatic issue, including recent DILI from another compound.
• Tested athletes — WADA-banned; metabolites are detectable in urine for up to ~22 days post-administration per Fragkaki 2018, and realistically longer with the long terminal half-life.
• Running without a PCT plan — the "SARMs don't need PCT" line is wrong at community doses. Enclomiphene or nolvadex, non-negotiable.

Gender-specific and PCT considerations#

Women: LGD is not the SARM to pick. The anabolic:androgenic ratio looks clean on paper (~500:1) but real-world virilization at anything above 1–2 mg/day is reported consistently enough that the conservative play is low-dose ostarine (5–10 mg/day) instead. Voice changes are the irreversible one — if you notice them, stop immediately.

Men running a hair stack: add topical fin 0.1% or RU58841 50 mg/day throughout cycle if you're MPB-predisposed. Oral finasteride does not block LGD at the AR — LGD isn't a 5-AR substrate — so topical AR antagonism is the right tool.

PCT: mini-PCT with enclomiphene 12.5 mg/day × 4 weeks is the cleanest protocol for a 5–10 mg cycle; bump to nolvadex 20/20/10/10 for 10–20 mg cycles or anyone who felt strongly suppressed mid-cycle. Start 24 h after the last dose — LGD's 24–36 h half-life means there's no clearance gap to wait out. Pull a full hormone panel 4–6 weeks post-PCT to confirm LH, FSH, and total T are back in range before considering the next cycle.